Precision Medicine for Chronic Myelomonocytic Leukaemia: Phase II Trial Studying the Efficacy of Lenzilumab or High Dose Ascorbate plus Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort
GA ID:
Agency:
Department of Health and Aged Care
Publish Date:
29-Jun-2020
Category:
Health and Medical Research
Grant Term:
1-Jun-2020
to
31-May-2023
Value (AUD):
$1,619,122.00
Recipient Name:
University of Adelaide
Last Updated:
29-Jun-2020 12:15 pm (ACT Local Time)